Celularity Closes $11M Secured Convertible Financing, Settles Helena Dispute with 2.7M Shares
CELU has more than doubled off its 52-week low of $0.56.
Summary
Celularity closed an $11M secured convertible note financing and settled its Helena dispute with 2.7M shares, while Philip Barach joined the board. The Trust's 13D/A discloses a Board Rights Agreement fixing the board at five directors with two Trust designees, and that the Trust holds 9,491,270 shares, 24.5% of Class A common stock.
Updated with an SEC SCHEDULE 13D/A filing · What changed
Updates
· SEC SCHEDULE 13D/A — The Trust's 13D/A discloses a Board Rights Agreement fixing the board at five directors with two Trust designees, and that the Trust holds 9,491,270 shares, 24.5% of Class A common stock.
Key Events · Financing and Capital Events · CELU
-
New · · SEC SCHEDULE 13D/A
Board Rights Agreement and Trust Holdings
The Trust's 13D/A discloses a Board Rights Agreement fixing the board at five directors with two Trust designees, and that the Trust holds 9,491,270 shares, 24.5% of Class A common stock.
-
$11.01M Initial Closing
Issued $11.01M of senior secured convertible notes at $1.50 conversion price, convertible into ~7.34M shares, plus warrants for ~4.04M shares at $1.50 exercise price.
-
Helena Settlement
Issued 700,000 shares converting $1.197M Exchange Note at $1.71/share, plus 2,000,000 additional shares as settlement consideration; make-whole provision tied to November 16, 2026 closing price.
-
Board Changes
Philip A. Barach appointed to Board effective September 24, 2026; Geoffrey Ling resigned same date.
-
Tranche 2 Option
Purchasers may elect up to $10M additional notes at $2.00 conversion/exercise price through September 30, 2027.
Analysis · CELU · Life Sciences
The initial $11.01 million tranche of a senior secured convertible note financing closed at $1.50 per share, with warrants for 4.04 million additional shares. A second tranche of up to $10 million at $2.00 per share is available through September 2027. Separately, the Helena dispute was settled by issuing 2.7 million shares — 700,000 from converting $1.197 million of debt at $1.71 and 2 million as settlement consideration, with a make-whole provision tied to the November 16 closing price. Philip Barach joined the board effective September 24, replacing Geoffrey Ling. The financing is secured by substantially all company assets and includes a 10% price reduction penalty if stockholder approval isn't obtained by December 19, 2026. A Board Rights Agreement fixes the board at five directors with two Trust designees, and the Trust holds 9,491,270 shares, 24.5% of Class A common stock.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELU was trading at $1.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.9M. The 52-week trading range was $0.56 to $2.55. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.